1
|
Díaz Del Arco C, Fernández Aceñero MJ, Ortega Medina L. Molecular Classifications in Gastric Cancer: A Call for Interdisciplinary Collaboration. Int J Mol Sci 2024; 25:2649. [PMID: 38473896 DOI: 10.3390/ijms25052649] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2024] [Revised: 02/21/2024] [Accepted: 02/22/2024] [Indexed: 03/14/2024] Open
Abstract
Gastric cancer (GC) is a heterogeneous disease, often diagnosed at advanced stages, with a 5-year survival rate of approximately 20%. Despite notable technological advancements in cancer research over the past decades, their impact on GC management and outcomes has been limited. Numerous molecular alterations have been identified in GC, leading to various molecular classifications, such as those developed by The Cancer Genome Atlas (TCGA) and the Asian Cancer Research Group (ACRG). Other authors have proposed alternative perspectives, including immune, proteomic, or epigenetic-based classifications. However, molecular stratification has not yet transitioned into clinical practice for GC, and little attention has been paid to alternative molecular classifications. In this review, we explore diverse molecular classifications in GC from a practical point of view, emphasizing their relationships with clinicopathological factors, prognosis, and therapeutic approaches. We have focused on classifications beyond those of TCGA and the ACRG, which have been less extensively reviewed previously. Additionally, we discuss the challenges that must be overcome to ensure their impact on patient treatment and prognosis. This review aims to serve as a practical framework to understand the molecular landscape of GC, facilitate the development of consensus molecular categories, and guide the design of innovative molecular studies in the field.
Collapse
Affiliation(s)
- Cristina Díaz Del Arco
- Department of Legal Medicine, Psychiatry and Pathology, School of Medicine, Complutense University of Madrid, 28040 Madrid, Spain
- Department of Pathology, Hospital Clínico San Carlos, Health Research Institute of the Hospital Clínico San Carlos (IdISSC), 28040 Madrid, Spain
| | - María Jesús Fernández Aceñero
- Department of Legal Medicine, Psychiatry and Pathology, School of Medicine, Complutense University of Madrid, 28040 Madrid, Spain
- Department of Pathology, Hospital Clínico San Carlos, Health Research Institute of the Hospital Clínico San Carlos (IdISSC), 28040 Madrid, Spain
| | - Luis Ortega Medina
- Department of Legal Medicine, Psychiatry and Pathology, School of Medicine, Complutense University of Madrid, 28040 Madrid, Spain
- Department of Pathology, Hospital Clínico San Carlos, Health Research Institute of the Hospital Clínico San Carlos (IdISSC), 28040 Madrid, Spain
| |
Collapse
|
2
|
Zhu J, Xu Z, Wu P, Zeng C, Peng C, Zhou Y, Xue Q. MicroRNA-92a-3p Inhibits Cell Proliferation and Invasion by Regulating the Transcription Factor 21/Steroidogenic Factor 1 Axis in Endometriosis. Reprod Sci 2023; 30:2188-2197. [PMID: 36650372 PMCID: PMC10310800 DOI: 10.1007/s43032-021-00734-9] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2021] [Accepted: 09/02/2021] [Indexed: 01/18/2023]
Abstract
Endometriosis (EMS) is an estrogen-dependent disease. However, little is known about the regulation of estrogen, a potential therapeutic target, in EMS, which remains very poorly managed in the clinic. We hypothesized that microRNAs (miRNAs) can be exploited therapeutically to regulate transcription factor 21 (TCF21) and steroidogenic factor-1 (SF-1) gene expression. In our study, paired eutopic and ectopic endometrial samples were obtained from women with EMS and processed by a standard protocol to obtain human endometrial stromal cells (EMs) for in vitro studies. We found that miR-92a-3p levels were decreased in ectopic endometrium and ectopic stromal cells (ESCs) compared with paired eutopic lesions. miR-92a-3p overexpression significantly suppressed the proliferation and migration of ESCs, whereas a decreased level of miR-92a-3p generated the opposite results. Next, we identified TCF21 as a candidate target gene of miR-92a-3p. In vitro cell experiments showed that miR-92a-3p negatively regulated the expression of TCF21 and its downstream target gene SF-1. Moreover, cell proliferation and invasion ability decreased after the silencing of SF-1 and increased after SF-1 overexpression. We also observed that silencing SF-1 while inhibiting miR-92a-3p partially blocked the increase in cell proliferation and invasion ability caused by miR-92a-3p knockdown while overexpressing both SF-1 and miR-92a-3p mitigated the impairment in cell proliferation and invasion ability caused by miR-92a-3p overexpression. Our results may provide a novel potential therapeutic target for the treatment of EMS.
Collapse
Affiliation(s)
- Jingwen Zhu
- Department of Obstetrics and Gynecology, Peking University First Hospital, No.1 Xi'anmen Street, Beijing, 100034, China
| | - Zijin Xu
- Department of Reproductive Medicine, Key Laboratory for Major Obstetric Diseases of Guangdong Province, and Key Laboratory for Reproduction and Genetics of Guangdong Higher Education Institutes, the Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
| | - Peili Wu
- Department of Obstetrics and Gynecology, Peking University First Hospital, No.1 Xi'anmen Street, Beijing, 100034, China
| | - Cheng Zeng
- Department of Obstetrics and Gynecology, Peking University First Hospital, No.1 Xi'anmen Street, Beijing, 100034, China
| | - Chao Peng
- Department of Obstetrics and Gynecology, Peking University First Hospital, No.1 Xi'anmen Street, Beijing, 100034, China
| | - Yingfang Zhou
- Department of Obstetrics and Gynecology, Peking University First Hospital, No.1 Xi'anmen Street, Beijing, 100034, China
| | - Qing Xue
- Department of Obstetrics and Gynecology, Peking University First Hospital, No.1 Xi'anmen Street, Beijing, 100034, China.
| |
Collapse
|
3
|
Nguyen NNY, Choi TG, Kim J, Jung MH, Ko SH, Shin Y, Kang I, Ha J, Kim SS, Jo YH. A 70-Gene Signature for Predicting Treatment Outcome in Advanced-Stage Cervical Cancer. MOLECULAR THERAPY-ONCOLYTICS 2020; 19:47-56. [PMID: 33024818 PMCID: PMC7530249 DOI: 10.1016/j.omto.2020.09.001] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/12/2020] [Accepted: 09/02/2020] [Indexed: 02/06/2023]
Abstract
Cervical cancer is the fourth most common cancer in women worldwide. The current approaches still have limitations in predicting the therapy outcome of each individual because of cancer heterogeneity. The goal of this study was to establish a gene expression signature that could help when choosing the right therapeutic method for the treatment of advanced-stage cervical cancer. The 666 patients were collected from four independent datasets. The 70-gene expression signature was established using univariate Cox proportional hazard regression analysis. The 70-gene signature was significantly different between low- and high-risk groups in the training dataset (p = 4.24e-6) and in the combined three validation datasets (p = 4.37e-3). Treatment of advanced-stage cancer patients in the high-risk group with molecular-targeted therapy combined with chemoradiotherapy yielded a better survival rate than with only chemoradiotherapy (p = 0.0746). However, treatment of the patients in the low-risk group with the combined therapy resulted in significantly lower survival (p = 0.00283). Functional classification of 70 genes revealed involvement of the angiogenesis pathway, specifically phosphatidylinositol 3-kinase signaling (p = 0.040), extracellular matrix organization (p = 0.0452), and cell adhesion (p = 0.011). The 70-gene signature could predict the prognosis and indicate an optimal therapeutic modality in molecular-targeted therapy or chemotherapy for advanced-stage cervical cancer.
Collapse
Affiliation(s)
- Ngoc Ngo Yen Nguyen
- Department of Biomedical Science, Graduate School, Kyung Hee University, Seoul 02447, Republic of Korea.,Biomedical Science Institute, Kyung Hee University, Seoul 02447, Republic of Korea
| | - Tae Gyu Choi
- Biomedical Science Institute, Kyung Hee University, Seoul 02447, Republic of Korea.,Department of Biochemistry and Molecular Biology, School of Medicine, Kyung Hee University, Seoul 02447, Republic of Korea
| | - Jieun Kim
- Department of Biomedical Science, Graduate School, Kyung Hee University, Seoul 02447, Republic of Korea.,Biomedical Science Institute, Kyung Hee University, Seoul 02447, Republic of Korea
| | - Min Hyung Jung
- Department of Obstetrics and Gynecology, School of Medicine, Kyung Hee Medical Center, Kyung Hee University, Seoul 02447, Republic of Korea
| | - Seok Hoon Ko
- Department of Emergency Medicine, School of Medicine, Kyung Hee Medical Center, Kyung Hee University, Seoul 02447, Republic of Korea
| | - Yoonhwa Shin
- Department of Biomedical Science, Graduate School, Kyung Hee University, Seoul 02447, Republic of Korea.,Biomedical Science Institute, Kyung Hee University, Seoul 02447, Republic of Korea
| | - Insug Kang
- Biomedical Science Institute, Kyung Hee University, Seoul 02447, Republic of Korea.,Department of Biochemistry and Molecular Biology, School of Medicine, Kyung Hee University, Seoul 02447, Republic of Korea
| | - Joohun Ha
- Biomedical Science Institute, Kyung Hee University, Seoul 02447, Republic of Korea.,Department of Biochemistry and Molecular Biology, School of Medicine, Kyung Hee University, Seoul 02447, Republic of Korea
| | - Sung Soo Kim
- Biomedical Science Institute, Kyung Hee University, Seoul 02447, Republic of Korea.,Department of Biochemistry and Molecular Biology, School of Medicine, Kyung Hee University, Seoul 02447, Republic of Korea
| | - Yong Hwa Jo
- Biomedical Science Institute, Kyung Hee University, Seoul 02447, Republic of Korea.,Department of Biochemistry and Molecular Biology, School of Medicine, Kyung Hee University, Seoul 02447, Republic of Korea
| |
Collapse
|
4
|
Li X, Dong W, Qu X, Zhao H, Wang S, Hao Y, Li Q, Zhu J, Ye M, Xiao W. Molecular dysexpression in gastric cancer revealed by integrated analysis of transcriptome data. Oncol Lett 2017; 13:3177-3185. [PMID: 28521423 DOI: 10.3892/ol.2017.5798] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2015] [Accepted: 11/30/2016] [Indexed: 02/07/2023] Open
Abstract
Gastric cancer (GC) is often diagnosed in the advanced stages and is associated with a poor prognosis. Obtaining an in depth understanding of the molecular mechanisms of GC has lagged behind compared with other cancers. This study aimed to identify candidate biomarkers for GC. An integrated analysis of microarray datasets was performed to identify differentially expressed genes (DEGs) between GC and normal tissues. Gene ontology and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were then performed to identify the functions of the DEGs. Furthermore, a protein-protein interaction (PPI) network of the DEGs was constructed. The expression levels of the DEGs were validated in human GC tissues using reverse transcription-quantitative polymerase chain reaction (RT-qPCR). A set of 689 DEGs were identified in GC tissues, as compared with normal tissues, including 202 upregulated DEGs and 487 downregulated DEGs. The KEGG pathway analysis suggested that various pathways may play important roles in the pathology of GC, including pathways related to protein digestion and absorption, extracellular matrix-receptor interaction, and the metabolism of xenobiotics by cytochrome P450. The PPI network analysis indicated that the significant hub proteins consisted of SPP1, TOP2A and ARPC1B. RT-qPCR validation indicated that the expression levels of the top 10 most significantly dysexpressed genes were consistent with the illustration of the integrated analysis. The present study yielded a reference list of reliable DEGs, which represents a robust pool of candidates for further evaluation of GC pathogenesis and treatment.
Collapse
Affiliation(s)
- Xiaomei Li
- Department of Oncology, The First Affiliated Hospital of PLA General Hospital, Beijing 100048, P.R. China.,Department of Oncology, PLA General Hospital, Beijing 100853, P.R. China
| | - Weiwei Dong
- Department of Oncology, The First Affiliated Hospital of PLA General Hospital, Beijing 100048, P.R. China.,Department of Oncology, PLA General Hospital, Beijing 100853, P.R. China
| | - Xueling Qu
- Department of Oncology, The First Affiliated Hospital of PLA General Hospital, Beijing 100048, P.R. China.,Graduate School Department of Oncology, Medical College of Liaoning, Jinzhou, Liaoning 121001, P.R. China
| | - Huixia Zhao
- Department of Oncology, The First Affiliated Hospital of PLA General Hospital, Beijing 100048, P.R. China
| | - Shuo Wang
- Department of Oncology, The First Affiliated Hospital of PLA General Hospital, Beijing 100048, P.R. China
| | - Yixin Hao
- Department of Oncology, The First Affiliated Hospital of PLA General Hospital, Beijing 100048, P.R. China
| | - Qiuwen Li
- Department of Oncology, The First Affiliated Hospital of PLA General Hospital, Beijing 100048, P.R. China
| | - Jianhua Zhu
- Department of Oncology, The First Affiliated Hospital of PLA General Hospital, Beijing 100048, P.R. China
| | - Min Ye
- Department of Oncology, The First Affiliated Hospital of PLA General Hospital, Beijing 100048, P.R. China
| | - Wenhua Xiao
- Department of Oncology, The First Affiliated Hospital of PLA General Hospital, Beijing 100048, P.R. China
| |
Collapse
|
5
|
El-Husny A, Raiol-Moraes M, Amador M, Ribeiro-Dos-Santos AM, Montagnini A, Barbosa S, Silva A, Assumpção P, Ishak G, Santos S, Pinto P, Cruz A, Ribeiro-Dos-Santos Â. CDH1 mutations in gastric cancer patients from northern Brazil identified by Next- Generation Sequencing (NGS). Genet Mol Biol 2016; 39:189-98. [PMID: 27192129 PMCID: PMC4910547 DOI: 10.1590/1678-4685-gmb-2014-0342] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2014] [Accepted: 07/23/2015] [Indexed: 12/20/2022] Open
Abstract
Gastric cancer is considered to be the fifth highest incident tumor worldwide and the third leading cause of cancer deaths. Developing regions report a higher number of sporadic cases, but there are only a few local studies related to hereditary cases of gastric cancer in Brazil to confirm this fact. CDH1 germline mutations have been described both in familial and sporadic cases, but there is only one recent molecular description of individuals from Brazil. In this study we performed Next Generation Sequencing (NGS) to assess CDH1 germline mutations in individuals who match the clinical criteria for Hereditary Diffuse Gastric Cancer (HDGC), or who exhibit very early diagnosis of gastric cancer. Among five probands we detected CDH1 germline mutations in two cases (40%). The mutation c.1023T > G was found in a HDGC family and the mutation c.1849G > A, which is nearly exclusive to African populations, was found in an early-onset case of gastric adenocarcinoma. The mutations described highlight the existence of gastric cancer cases caused by CDH1 germline mutations in northern Brazil, although such information is frequently ignored due to the existence of a large number of environmental factors locally. Our report represent the first CDH1 mutations in HDGC described from Brazil by an NGS platform.
Collapse
Affiliation(s)
- Antonette El-Husny
- Laboratório de Genética Humana e Médica (LGHM), Instituto de Ciências Biológicas, Universidade Federal do Pará (UFPA), Belém, PA, Brazil.,Rede de Pesquisa em Genômica Populacional Humana, Universidade Federal do Pará (UFPA), Belém, PA, Brazil
| | - Milene Raiol-Moraes
- Laboratório de Genética Humana e Médica (LGHM), Instituto de Ciências Biológicas, Universidade Federal do Pará (UFPA), Belém, PA, Brazil.,Rede de Pesquisa em Genômica Populacional Humana, Universidade Federal do Pará (UFPA), Belém, PA, Brazil
| | - Marcos Amador
- Laboratório de Genética Humana e Médica (LGHM), Instituto de Ciências Biológicas, Universidade Federal do Pará (UFPA), Belém, PA, Brazil.,Rede de Pesquisa em Genômica Populacional Humana, Universidade Federal do Pará (UFPA), Belém, PA, Brazil
| | - André M Ribeiro-Dos-Santos
- Laboratório de Genética Humana e Médica (LGHM), Instituto de Ciências Biológicas, Universidade Federal do Pará (UFPA), Belém, PA, Brazil.,Rede de Pesquisa em Genômica Populacional Humana, Universidade Federal do Pará (UFPA), Belém, PA, Brazil
| | - André Montagnini
- Instituto Sírio-Libanês de Ensino e Pesquisa, Hospital Sírio-Libanês, São Paulo, SP, Brazil
| | - Silvanira Barbosa
- Laboratório de Polimorfismo de DNA - Instituto de Ciências Biológicas, Universidade Federal do Pará (UFPA), Belém, PA, Brazil
| | - Artur Silva
- Rede de Pesquisa em Genômica Populacional Humana, Universidade Federal do Pará (UFPA), Belém, PA, Brazil.,Laboratório de Polimorfismo de DNA - Instituto de Ciências Biológicas, Universidade Federal do Pará (UFPA), Belém, PA, Brazil
| | - Paulo Assumpção
- Rede de Pesquisa em Genômica Populacional Humana, Universidade Federal do Pará (UFPA), Belém, PA, Brazil.,Núcleo de Pesquisas em Oncologia, Universidade Federal do Pará (UFPA), Belém, PA, Brazil
| | - Geraldo Ishak
- Rede de Pesquisa em Genômica Populacional Humana, Universidade Federal do Pará (UFPA), Belém, PA, Brazil.,Núcleo de Pesquisas em Oncologia, Universidade Federal do Pará (UFPA), Belém, PA, Brazil.,Hospital Universitário João de Barros Barreto, Universidade Federal do Pará (UFPA), Belém, PA, Brazil
| | - Sidney Santos
- Laboratório de Genética Humana e Médica (LGHM), Instituto de Ciências Biológicas, Universidade Federal do Pará (UFPA), Belém, PA, Brazil.,Rede de Pesquisa em Genômica Populacional Humana, Universidade Federal do Pará (UFPA), Belém, PA, Brazil.,Núcleo de Pesquisas em Oncologia, Universidade Federal do Pará (UFPA), Belém, PA, Brazil
| | - Pablo Pinto
- Laboratório de Genética Humana e Médica (LGHM), Instituto de Ciências Biológicas, Universidade Federal do Pará (UFPA), Belém, PA, Brazil.,Núcleo de Pesquisas em Oncologia, Universidade Federal do Pará (UFPA), Belém, PA, Brazil
| | - Aline Cruz
- Laboratório de Genética Humana e Médica (LGHM), Instituto de Ciências Biológicas, Universidade Federal do Pará (UFPA), Belém, PA, Brazil.,Núcleo de Pesquisas em Oncologia, Universidade Federal do Pará (UFPA), Belém, PA, Brazil
| | - Ândrea Ribeiro-Dos-Santos
- Laboratório de Genética Humana e Médica (LGHM), Instituto de Ciências Biológicas, Universidade Federal do Pará (UFPA), Belém, PA, Brazil.,Rede de Pesquisa em Genômica Populacional Humana, Universidade Federal do Pará (UFPA), Belém, PA, Brazil.,Núcleo de Pesquisas em Oncologia, Universidade Federal do Pará (UFPA), Belém, PA, Brazil
| |
Collapse
|